BOSTON, Jan. 25 /PRNewswire-FirstCall/ -- Surface Logix Inc. announced
today the appointment of Steven Gillis, Ph.D. of ARCH Venture Partners to the
Company's Board of Directors. As a member of the Board, Dr. Gillis will
provide strategic advice on the Company's pipeline of new drugs and guidance
on advancing new drugs through the clinical development process.
"I am extremely pleased to welcome Steve to the Surface Logix Board," said
Jim Mahoney, CEO of Surface Logix. "During his extensive career, Steve helped
to build some of the most successful and highly regarded companies in this
industry. His experience and strategic insights will be invaluable to Surface
Logix as we are now advancing our programs towards clinical proof of concept."
Steven Gillis, Ph.D. joined ARCH in 2005 as a Venture Partner focused on
the evaluation of new life science technologies and also on the development
and growth of ARCH's biotechnology portfolio companies. Prior to ARCH, Dr.
Gillis founded Corixa Corp. (acquired by GlaxoSmithKline in July 2005), where
he served as the company's Chief Executive Officer since its inception and as
its Chairman since 1999.
Dr. Gillis was also a founder and director of Immunex Corporation. From
1981 until his departure in 1994, Dr. Gillis served as Immunex's Director of
Research and Development, Chief Scientific Officer and Chief Executive Officer
of Immunex's Research and Development subsidiary. Dr. Gillis was interim Chief
Executive Officer of Immunex following its majority purchase by American
Cyanamid Company and he remained a member of the Board of Directors until
1997. Immunex was acquired by Amgen Inc. in 2002.
An immunologist by training, Dr. Gillis has over 300 peer-reviewed
publications in the areas of molecular and tumor immunology. He is credited as
being a pioneer in the field of cytokines and cytokine receptors. Dr. Gillis
received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth
College in 1978.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create
new small molecule drugs that are optimized to meet the challenges of human
physiology. The Company is advancing multiple internal programs focused
primarily on cardiovascular disease, oncology and metabolic disorders and
works with strategic partners to create differentiated new chemical entities.
For more information, please visit http://www.surfacelogix.com
Contact:
David H. Donabedian, Ph.D.
Vice President, Business Development
Surface Logix Inc.
617.746.8520
Media:
Kari Watson
MacDougall Biomedical Communications, Inc.
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
David H. Donabedian, Ph.D., Vice President,
Business Development of Surface Logix Inc., +1-617-746-8520; or
Media: Kari Watson of MacDougall Biomedical Communications, Inc.,
+1-508-647-0209
|
